Johnson & Johnson has pulled ahead of rival AstraZeneca Plc in a race to dominate the blockbuster market for lung cancer treatment, but data from a forthcoming study could quickly shake up the ...

Key Takeaways Shares of several drugmakers fell Wednesday as the threat of tariffs on the industry loomed.President Donald ...

President Donald Trump plans to announce a “major” tariff on pharmaceutical imports soon, Reuters reports. Trump said the tariff will ...

Plus, Johnson & Johnson will spend $55 billion ... in investment compared to the previous four years. And finally, AstraZeneca will invest $2.5 billion in a new research center in Beijing, in ...

As the countdown to the launch of its first therapeutic continues, Rocket Pharmaceuticals is fueling up its commercial team.

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...

According to a factsheet published by the Trump administration, pharmaceuticals are exempted from the tariffs – for now.

Johnson & Johnson: Top-Line Cancer Data Looks Increasingly Likely to Threaten AstraZeneca's Tagrisso Johnson & Johnson reported positive top-line Mariposa data for its cancer drugs Rybrevant plus ...

Lawyers for AstraZeneca, Bristol-Myers Squibb, and Johnson & Johnson argued at a panel hearing in Philadelphia late last week that the negotiation powers – introduced as part of the Biden ...

Johnson & Johnson is a global leader in the ... which closed at $96.63 on Jan. 23. AstraZeneca is one of the largest pure-play pharmaceutical companies in the world. Its leading commercial drugs ...

A judge dismissed an attempt to use a bankruptcy court to resolve tens of thousands of claims that the company’s talcum power ...